ArticlePolymers2025
Study on the Preparation and Modification of a Novel Bio-Based Cardanol-Furfurylamine Oxazine Resin.
Article in Polymers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, a novel bio-based oxazine resin was synthesized through the reaction of naturally renewable materials: cardanol and furfurylamine. The molecular structure of the target product was confirmed via comprehensive characterization techniques, including Fourier-transform Infrared Spectroscopy (FT-IR), Gel Permeation Chromatography (GPC), Mass Spectrometry (MS), and Nuclear Magnetic Resonance (NMR). Differential Scanning Calorimetry (DSC) revealed that the curing process of cardanol-furfurylamine oxazine (CFZ) exhibited three exothermic peaks (~140, ~240, ~270 °C), which not only helped to optimize the processing conditions but also effectively enhanced the material properties. In the modification experiments, CFZ had been blended and cured with benzoxazine (BZ) at the mass ratios of 2:98, 5:95, 10:90, 20:80, and 40:60. Dynamic Mechanical Thermal Analysis (DMTA) further showed an elevated Loss Factor (tan δ) peak of CFZ-BZ resin, suggesting significantly enhanced toughness. Notably, when the content of the CFZ resin in the composite reached only 5%, the storage modulus achieved its maximum value, highlighting that minimal addition of CFZ resin can optimize the rigidity of the composite, which would drastically reduce material costs and simplify the process. Impact strength testing demonstrated that the impact resistance of CFZ-BZ resin was 6.42 times higher than that of pristine BZ. By integrating renewable materials with rational molecular design, this novel oxazine resin synergistically combines high-temperature resistance, superior toughness, and efficient modification at low loading, positioning it as a promising candidate to replace conventional petroleum-based resins in aerospace, renewable energy, and electronic packaging applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.